World Graft Versus Host Disease Treatment Market Forecast Epidemiology 2022-2027: 134+ Molecules in Various Stages of Development
2022-06-10
并购合作
DUBLIN, June 10, 2022 /PRNewswire/ -- The "Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to
ResearchAndMarkets.com's offering.
The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.
The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.
SEGMENT ANALYSIS
Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.
Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space
Market Segmentation by Drug Class
Corticosteroids
Kinase Inhibitors
Calcineurin Inhibitors
TNF-Alpha Inhibitors
Other Class of Drugs
Market Segmentation by Treatment Type
GVHD ProphylaxisGVHD Prophylaxis
Market Segmentation by Gender Type
Males
Females
GEOGRAPHIC ANALYSIS
The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.
Market Segmentation by Geography
North America
US
Europe
France
Germany
Italy
UK
Spain
China
Japan
VENDOR ANALYSIS
With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.
Takeda Pharmaceutical Co Ltd (Takeda)
Mesoblast
Gsk
Other Prominent Vendors
Neovii
ElsaLys Biotech
Altrubio
CTTQ
Equillium
Janssen (johnson & johnson)
For more information about this report visit https://www.researchandmarkets.com/r/r6dtoh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。